Endpoint Selection and Relative (Versus Absolute) Risk Reporting in Published Medication Trials
- 138 Downloads
The use of surrogate and composite endpoints, disease-specific mortality as an endpoint, and relative (rather than absolute) risk reporting in clinical trials may produce results that are misleading or difficult to interpret.
To describe the prevalence of these endpoints and of relative risk reporting in medication trials.
DESIGN AND MAIN MEASURES
We analyzed all randomized medication trials published in the six highest impact general medicine journals between June 1, 2008 and September 30, 2010 and determined the percentage using these endpoints and the percentage reporting results in the abstract exclusively in relative terms.
We identified 316 medication trials, of which 116 (37%) used a surrogate primary endpoint and 106 (34%) used a composite primary endpoint. Among 118 trials in which the primary endpoint involved mortality, 32 (27%) used disease-specific mortality rather than all-cause mortality. Among 157 trials with positive results, 69 (44%) reported these results in the abstract exclusively in relative terms. Trials using surrogate endpoints and disease-specific mortality as an endpoint were more likely to be exclusively commercially funded (45% vs. 29%, difference 15% [95% CI 5%–26%], P = 0.004, and 39% vs. 16%, difference 22% [95% CI 6%-37%], P = 0.007, respectively). Trials using surrogate endpoints were more likely to report positive results (66% vs. 49%, difference 17% [95% CI 5%–28%], P = 0.006) while those using mortality endpoints were less likely to be positive (46% vs. 62%, difference −16% [95% CI −27%–−4%], P = 0.01).
The use of surrogate and composite endpoints, endpoints involving disease-specific mortality, and relative risk reporting is common. Articles should highlight the limitations of these endpoints and should report results in absolute terms.
KEY WORDSsurrogate endpoints composite endpoints disease-specific mortality relative risk reduction
We have listed everyone who made substantial contributions to this analysis as authors of the article.
This study was unfunded (i.e. it received no internal or external funding).
This work was presented as a poster at the 2011 Society of General Internal Medicine National Meeting in Phoenix, Arizona.
Conflict of Interest
- 9.Ferreira-González I, Busse JW, Heels-Ansdell D, Montori VM, Akl EA, Bryant DM, Alonso-Coello P, Alonso J, Worster A, Upadhye S, Jaeschke R, Schünemann HJ, Permanyer-Miralda G, Pacheco-Huergo V, Domingo-Salvany A, Wu P, Mills EJ, Guyatt GH. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ. 2007;334(7597):786.PubMedCrossRefGoogle Scholar
- 21.Science journal citation reports ISI: Summer 2008. Thomson Reuters Web site. http://scientific.thomson.com/products/jcr/. Accessed July 5, 2011.
- 23.Temple RJ. A regulatory authority’s opinion about surrogate endpoints. In: Nimmo WS, Tucker GT, eds. Clinical Measurement in Drug Evaluation. New York: Wiley; 1995.Google Scholar
- 30.Guyatt G, Rennie D, Meade MO, Cook DJ. Can one be confident that the component endpoints share similar relative risk reductions? Users’ guides to the medical literature. Chapter 10.4. Composite Endpoints.Google Scholar